Effects of MAPK and PI3K Pathways on PD-L1 Expression in Melanoma

2014329 citationsJournal Articlegreen Open Access

Authors

Mohammad Atefi

Earl Avramis

Thomas G. Graeber · University of California, Los Angeles

Begonya Comin-Anduix · University of California, Los Angeles

Abstract

In melanoma cell lines, including BRAFi-resistant cells, PD-L1 expression is variably regulated by oncogenic signaling pathways. PD-L1-exposed lymphocytes decrease MAPK signaling, which is corrected by exposure to vemurafenib, providing potential benefits of combining this drug with immunotherapies.

Topics & Keywords

Melanoma and MAPK Pathways Cancer Immunotherapy and Biomarkers

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Clinical Cancer Research

Volume 20, Issue 13, pp. 3446-3457

DOI: 10.1158/1078-0432.ccr-13-2797

Field-Weighted Citation Impact: 18.65